Friday, 20 Oct 2017

You are here

20% Price Hike Among Pfizer Drugs

The increasing cost of drug has been the subject of concern and review - by legislators, reporters and patients.

The Financial Times has reviewed the annual price increases for the 91 drugs in Pfizers portfolio, showing an average price increase by 20 percent in the past year.

This includes Viagra and Lyrica.

Drug pricing has become a highly publicized and contentious issue. Many manufacturers are pledging to be more transparent to address the concerns of payers, patients and politicians.

Price hikes are common.  The cost of three top-selling TNF inhibitors has risen from $18,000 per year in 2000 to nearly $48,000 per year in 2017.

Companies like Sanofi, AbbVie, Allergan and Novo Nordisk have announced their price increases would be in the single-digit percentage range this year.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Rheumatologists are Slow to Change DMARDs

The paradigm of rheumatoid arthritis (RA) therapy mandates early diagnosis and aggressive treatment.  Yet a recent cohort study has shown that RA patients with moderate to high disease activity (MHDAS) were met with infrequent DMARD adjustments; with median time to DMARD adjustment being 5 months and median time to low disease activity (LDAS) was roughly 10 months. 

Novel Gel Drug Delivery Developed for Rheumatoid Arthritis

Scientists at the Institute for Basic Science have invented a hydrogel capable of delivering drug at sites of inflammation in disorders such as rheumatoid arthritis. Published in Advanced Materials, this jelly-like material could be used to absorb extra fluids in swelling joints and release drugs wherever nitric oxide is produced in abundance.

2016 EULAR Guidelines on RA Management

The management of rheumatoid arthritis (RA) has evolved significantly with time.  Nevertheless, there are still some uncertainties - such as when, what and which biologic or novel therapy should be used.

New EULAR Guidelines for Ultrasound Use

In the current issue of ARD, the European League Against Rheumatism (EULAR) has revised and updated its 2001 guideline for musculoskeletal (MS) ultrasound (US) in rheumatology; this time incorporating new advances, technological developments and use indications in rheumatology. EULAR has provided this as an educational tool and standard reference for MSUS practice and research in rheumatology.

The Unregulated $37 Billion Supplement Industry

In 1994 there were 600 supplement companies, producing 4,000 OTC supplement products for a total revenue of about $4 billion. Today we have close to 6,000 companies, producting nearly 75,000 supplement products, bringing in $37 billion annually.  And all of this is regulated by 26 people and a budget of $5 million at the FDA.